Table 2.
Relative expression of miR-21 | Relative expression of miR-375 | ||||||
---|---|---|---|---|---|---|---|
|
|||||||
n | High | Low | P-value | High | Low | P-value | |
Total | 46 | 24 (52.2%) | 22 (47.8%) | 23 (50.0%) | 23 (50.0%) | ||
Gender | |||||||
Male | 42 | 22 (52.4%) | 20 (47.6%) | 20 (47.6%) | 22 (52.4%) | ||
Female | 4 | 2 (50.0%) | 2 (50.0%) | 1.000 | 3 (75.0%) | 1 (25.0%) | 0.608 |
Age (y) | |||||||
< 65 | 22 | 12(54.5%) | 10 (45.5%) | 12 (54.5%) | 10 (45.5%) | ||
≤ 65 | 24 | 12(50.0%) | 12 (50.0%) | 0.990 | 11 (45.8%) | 13 (54.2%) | 0.768 |
T stage | |||||||
T0/1/2 | 21 | 12 (57.1%) | 9 (42.9%) | 13 (61.9%) | 8 (38.1%) | ||
T3/4 | 25 | 12 (48.0%) | 13 (52.0%) | 0.747 | 10 (40.0%) | 15 (60.0%) | 0.236 |
N stage | |||||||
Negative | 32 | 17 (53.1%) | 15 (46.9%) | 18 (56.3%) | 14 (43.8%) | ||
Positive | 14 | 7 (50.0%) | 7 (50.0%) | 1.000 | 5 (35.7%) | 9 (64.3%) | 0.336 |
Stage | |||||||
Low (I-II) | 31 | 13 (41.9%) | 18 (58.1%) | 19 (61.3%) | 12 (38.7%) | ||
High (III-IV) | 15 | 11 (73.3%) | 4 (26.7%) | 0.092 | 4 (26.7%) | 11 (73.3%) | 0.059 |
Localization | |||||||
Glottic | 33 | 18 (54.5%) | 15 (45.5%) | 20 (60.6%) | 13 (39.4%) | ||
Supraglottic | 11 | 5 (45.5%) | 6 (54.5%) | 0.862 | 2 (18.2%) | 9 (81.8%) | 0.037 |
Subglottic | 2 | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | ||
Smokinga | |||||||
Negative | 12 | 5 (41.7%) | 7 (58.3%) | 6 (50.0%) | 6 (50.0%) | ||
Positive | 31 | 18 (58.1%) | 13 (41.9%) | 0.531 | 15 (48.4%) | 16 (51.6%) | 1.000 |
Alcoholb | |||||||
Negative | 22 | 11 (50.0%) | 11 (50.0%) | 15 (68.2%) | 7 (31.8%) | ||
Positive | 19 | 10 (52.6%) | 9 (47.4%) | 1.000 | 6 (31.6%) | 13 (68.4%) | 0.043 |
Data missing in 3 samples;
Data missing in 5 samples; p < 0.05.
Note: Correlation between the expression of miRNA-21 and miRNA-375 and clinicopathological factors in laryngeal SCC patients. p values, as calculated using the χ2 or Fisher’s exact test, are shown, with p < 0.05 considered statistically significant.